Journal for ImmunoTherapy of Cancer (Nov 2023)

708 A phase 1/2 study of rinatabart sesutecan (PRO1184), a novel folate receptor alpha-directed antibody-drug conjugate, in patients with locally advanced and/or metastatic solid tumors

  • Jing Wang,
  • Jian Zhang,
  • Jun Zhang,
  • Ning Li,
  • Xiaohua Wu,
  • Elizabeth Lee,
  • Naomi Hunder,
  • Ying Cheng,
  • Debra L Richardson,
  • Erika Hamilton,
  • Lin Wu,
  • Ira Winer,
  • Ian Anderson,
  • Gottfried Konecny,
  • Douglas Orr,
  • Oladapo Yeku,
  • Sandip P Patel,
  • Sharon Ma,
  • Eric Song,
  • Justin A Call,
  • Lian Lu

DOI
https://doi.org/10.1136/jitc-2023-SITC2023.0708
Journal volume & issue
Vol. 11, no. Suppl 1

Abstract

Read online

No abstracts available.